Analyst Ratings January 30, 2026

William Blair Restarts Coverage of Cooper Companies, Assigns Outperform Rating

Analyst firm cites improving earnings actions, strategic review and valuation gap despite recent activist pressure

By Jordan Park COO
William Blair Restarts Coverage of Cooper Companies, Assigns Outperform Rating
COO

William Blair has resumed coverage of Cooper Companies (COO) with an Outperform rating, pointing to expected net income growth, recent operational moves to improve earnings and cash flow, and a valuation discount versus peers. The firm highlighted a strategic review that could separate CooperVision and CooperSurgical, while other analysts have raised price targets after a stronger-than-expected fiscal 2025 report.

Key Points

  • William Blair resumed coverage of Cooper Companies with an Outperform rating and expects net income growth this year based on InvestingPro data.
  • Cooper is conducting a strategic review considering a split of CooperVision and CooperSurgical; shares trade at an estimated 18x forward P/E, about a 10% discount to peers despite similar projected earnings growth.
  • Fiscal 2025 results beat expectations (revenue beat by $10 million; EPS beat by $0.04), prompting multiple firms to raise price targets to $100 and reiterate Buy/Outperform views.

Overview

William Blair has resumed coverage of Cooper Companies (NASDAQ: COO) and assigned the stock an Outperform rating. The firm’s call follows a stretch of activist investor engagement and a period of share underperformance, and it rests on expectations for net income growth this year as reported by InvestingPro data.

Context behind the new coverage

According to William Blair’s report, Cooper Companies has underperformed relative to the market for three years. Activist investor pressure began in the fall of 2025, and the company has since taken more assertive steps to lift earnings and cash flow while attempting to unlock shareholder value.

Central to those efforts is a strategic review that management announced, which is primarily focused on whether Cooper’s two main divisions - CooperVision (CVI) and CooperSurgical (CSI) - should be separated into independent entities. William Blair noted that shares currently trade at an 18x forward price-to-earnings multiple, roughly a 10% discount to peers, despite what the firm views as comparable earnings growth potential over the next couple of years.

Valuation and price targets

InvestingPro’s Fair Value assessment cited in the research suggests the stock is undervalued. Analyst price targets referenced in the firm’s research span from $73 to $100. For investors seeking additional analysis, InvestingPro makes a Pro Research Report available for Cooper Companies as well as for more than 1,400 other U.S. equities.

Recent financial and analyst updates

Cooper Companies reported fiscal 2025 results that exceeded consensus: revenue came in $10 million above expectations while earnings per share beat estimates by $0.04. Both the CVI and CSI divisions performed slightly ahead of expectations and together contributed to a 40 basis point outperformance on the adjusted operating margin line.

Following those results, multiple brokerages adjusted their views and price targets. Mizuho raised its price target to $100 and kept an Outperform rating. Needham lifted its target to $100 from $94 and maintained a Buy rating. Stifel reiterated its Buy rating as well, pointing to Cooper’s strong position in the contact lens market and the potential upside tied to a shift toward silicone hydrogel daily lenses.

Governance and leadership moves

As part of an agreement with investor Browning West, LP, Cooper Companies announced the appointment of Walt Rosebrough as an independent director effective January 2026. Rosebrough is slated to join the Corporate Governance & Nominating Committee and is being considered for the role of Chair by the end of 2026.

On the finance side, Brian G. Andrews has assumed the additional responsibilities of principal accounting officer while continuing in his roles as Executive Vice President, Chief Financial Officer, and Treasurer. Andrews succeeds Agostino Ricupati in that accounting officer role; Ricupati will continue with the company as Senior Vice President, Tax.


Conclusion

William Blair’s resumption of coverage with an Outperform rating comes amid a broader wave of analyst activity and company actions aimed at improving performance and corporate structure. The firm highlights a valuation gap relative to peers and expects net income growth this year, while other analysts have responded to stronger fiscal results by raising price targets and reaffirming positive ratings.

Risks

  • Ongoing activist investor involvement and the strategic review introduce execution and timing uncertainty for any potential separation of CooperVision and CooperSurgical - this affects corporate governance and market structure considerations in the healthcare and medical devices sectors.
  • Valuation disconnect: the stock trades at a discount to peers despite projected similar earnings growth, creating risk that market expectations or peer valuations shift before the company’s initiatives materially improve earnings - this impacts equity investors and the broader healthcare/medical device market.
  • Operational and leadership transitions, including the appointment of a new independent director and a change in the principal accounting officer role, carry integration and governance risks that could influence investor confidence in the healthcare and medtech sectors.

More from Analyst Ratings

KeyBanc Keeps Cautious View on LyondellBasell After Difficult Quarter, Cites Cash-Flow Limits vs. Dividend Feb 2, 2026 KeyBanc Sticks with Overweight on Murphy USA, Sees Near-Term Upside as Fuel Margins Improve Feb 2, 2026 Bernstein Boosts SanDisk Price Target to $1,000 After Robust Q2; Peers Follow Suit Feb 2, 2026 Piper Sandler Sticks With Overweight on Robinhood as Shares Pull Back Feb 2, 2026 Bernstein Raises Verizon Target to $48, Cites Strong Subscriber and FWA Gains Feb 2, 2026